Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences develops CRISPR genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies. Company updates center on vispacabtagene regedleucel, or vispa-cel, an anti-CD19 CAR-T therapy being evaluated in B cell non-Hodgkin lymphoma and large B cell lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.
Recurring announcements include clinical and translational data from the ANTLER and CaMMouflage trials, FDA designations and trial-design interactions, financial results, research and development spending, cash resources, pipeline prioritization, and medical or investor conference participation.
Caribou Biosciences (Nasdaq: CRBU) reported long-term ANTLER phase 1 data for vispa-cel, an allogeneic CD19 CAR-T, in second-line large B cell lymphoma (2L LBCL). In 27 optimized-dose patients, a single 80-million-cell infusion achieved 82% ORR, 67% CR, and 17.1-month median PFS.
The safety profile showed no graft-versus-host disease, no ≥grade 3 ICANS, one (4%) ≥grade 3 CRS, and serious infections and cytopenias in some patients. Caribou outlined the ANTLER-3 pivotal phase 3 trial, enrolling ~250 CD19-naïve 2L LBCL patients versus standard regimens, with PFS as the primary endpoint.
Caribou Biosciences (Nasdaq: CRBU) reported longer follow up data from the phase 1 CaMMouflage trial of CB-011, an off-the-shelf BCMA-targeted CAR-T for relapsed/refractory multiple myeloma.
At the recommended dose, a single infusion showed high response rates, deep MRD-negative remissions, and a manageable safety profile, plus a detailed case after prior BCMA CAR-T.
Caribou Biosciences (Nasdaq: CRBU) announced that president and CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35 p.m. ET in New York.
The live and archived webcasts will be accessible via the Events page on Caribou’s website for at least 30 days.
Caribou Biosciences (Nasdaq: CRBU) announced that its management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026 at 12:30 p.m. ET in New York.
A live webcast and replay will be available for at least 30 days on the Events page of Caribou’s website.
Caribou Biosciences (Nasdaq: CRBU) will feature its allogeneic CAR-T programs vispa-cel and CB-011 in oral presentations at the 2026 European Hematology Association Annual Meeting in Stockholm, June 11-14, 2026.
Presentations cover ANTLER and CaMMouflage phase 1 trials in lymphoma and multiple myeloma.
Caribou Biosciences (Nasdaq: CRBU) reported Q1 2026 results and clinical updates on May 7, 2026. Key items: FDA alignment on the pivotal ANTLER-3 vispa-cel trial design; RMAT designation for CB-011 with strong early response rates; Q1 cash of $118.6M and cash runway into 2H 2027.
Company expects longer follow-up data for vispa-cel and CB-011 in 2026 and is exploring funding options for the vispa-cel pivotal trial.
Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on May 13, 2026 at 8:40am PT in Las Vegas.
Webcast details and replay access are available via the company Events page; webcasts remain available for at least 30 days after the event.
Caribou Biosciences (Nasdaq: CRBU) announced the FDA granted RMAT designation to CB-011, an allogeneic anti-BCMA CAR-T for relapsed or refractory multiple myeloma.
RMAT follows promising CaMMouflage phase 1 dose‑escalation data: 92% ORR, 75% ≥CR, and 91% MRD negativity in 12 BCMA‑naïve patients at the recommended dose for expansion; dose expansion and additional 2026 data planned.
Caribou Biosciences (Nasdaq: CRBU) reported Q4 and full-year 2025 results and clinical updates on March 5, 2026. Key financials: FY2025 licensing revenue $11.2M, GAAP net loss $148.1M ($1.59/sh), non-recurring impairment $21.3M and $142.8M cash at year-end. Management expects cash to fund operations into 2H 2027 while exploring options to fully fund a vispa-cel pivotal trial.
Clinical: vispa-cel showed efficacy and durability in 2L LBCL comparable to autologous CAR-T; Caribou is engaging the FDA on pivotal design. CB-011 dose expansion for r/r multiple myeloma initiated with planned data updates in 2026.
Caribou Biosciences (Nasdaq: CRBU) said management will attend two investor conferences in February–March 2026. Key engagements include a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Feb 19, 2026 at 10:45 AM ET and a fireside chat at the Leerink Global Healthcare Conference in Miami on Mar 10, 2026 at 8:00 AM ET.
A webcast of the Leerink presentation will be available via the company Events page and accessible for at least 30 days after the event.